Seven-year-old Wyatt Hubbard will be one of the first children in the U.S. to be given the new breakthrough drug. It’s believed the drug will slow down the progression of the disease and maybe even help Wyatt gain back some lost muscle function. He is due to start the weekly treatment at Akron Children’s Hospital in Ohio.
Exondys 51 was approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) patients who have a rare mutation of dystrophin gene. It’s estimated that approximately 13 percent of DMD pateints have this mutation and will benefit from weekly injections of the drug. Find out more about Exondys 51 here.
Muscular Dystrophy News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.